|Agios Pharmaceuticals, Inc.|
38 Sidney Street
United States - Map
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its product candidates include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. The company is also developing AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
|Dr. David P. Schenkein M.D.,
Chief Exec. Officer and Director
|Dr. Lewis Clayton Cantley Ph.D.,
Co-Founder, Director, Member of Scientific Advisory Board and Member of Nominating & Corp. Governance Committee
|Mr. Glenn Goddard ,
Principal Financial Officer, Principal Accounting Officer and Sr. VP of Fin.
|Mr. John Duncan Higgons M.Sc (Economics),
Chief Operating Officer
|Dr. Scott Biller Ph.D.,
Chief Scientific Officer
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|